Navigation Links
China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Date:5/2/2008

ld decreased from 19.3% of total A/R at March 31, 2007, to 7.9% at March 31, 2008. Net cash flow from operating activities was $1.5 million in the three months ended March 31, 2008, compared to negative $2.2 million during the same time in the prior year. The improvement in operating cash flow was primarily due to the increase of net income and collection of older trade accounts receivables.

Ms. Li concluded, "In the first quarter of 2008, our acceleration in organic growth from our existing core products and new products launched after 2006 demonstrates the success of our dual growth strategy. China Pharma continues to focus on developing and marketing improved generic products for high incidence and high mortality diseases particular to the China market. With the rapidly growing economy and the Chinese Government's commitment to expand its rural cooperative medical system (CMS) by spending $1.3 billion to increase coverage from 51% to 100% in rural areas, we are well positioned in the Chinese pharmaceutical industry to continue to grow our revenue and net income throughout 2008 and beyond."

Conference Call

China Pharma will host a conference call on Tuesday, May 6 at 10:00 am EDT to discuss first quarter 2008 results. To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 591-6942 International callers should dial (617) 614-4909. The conference pass code is 32765641.

If you are unable to participate in the call at this time, a replay will be available on Tuesday, May 6, at 12:00 pm EDT, through Tuesday, May 13. To access the replay, dial (888) 286-8010. International callers should dial (617) 801-6888. The conference pass code is 89227480.

This conference call will be broadcast live over the Internet and can be accessed by copying and pasting this link into your web browser:

SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
2. DuPont Partnering with China to Increase Farm Productivity
3. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
4. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
5. Syngenta To Build Major Global Biotech Research Center in Beijing, China
6. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
7. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
8. CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China
9. China Bio Energy Reports Fiscal 2007 Financial Results
10. Transgenomic Opens Pharmacogenomics Laboratory in China
11. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Regis Technologies announced new potent compound ... substances. , Regis Technologies is proud to announce the ... Suite (PCS) for 2015. , Regis is a contract ... in Morton Grove, Illinois. The PCS addition will provide ... to about one kilogram per batch. , Regis’ ...
(Date:2/26/2015)... , Feb. 26, 2015  Epic Sciences announced ... Ph.D. will present at the 35th Annual Cowen and ... EST in the MIT Room, 3rd Floor. The conference ... Hotel in Boston, Mass. Epic is developing diagnostic ... of genomic and proteomic changes that occur during the ...
(Date:2/26/2015)... 26, 2015 CytomX, a biotechnology company developing ... that Sean McCarthy , D. Phil., chief executive ... Cowen and Company 35 th Annual Health Care ... presentation will take place at 4 p.m. EST on ... CytomX Therapeutics develops Probody™ therapeutics for the treatment of ...
(Date:2/26/2015)... Phosphate Therapeutics, today announces ... pivotal trial of PT20 in subjects with hyperphosphataemia ... has completed as the pre-specified number of randomisations ... leading UK-based scientists from the Medical Research Council ... novel phosphate binder that is based on proprietary ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3
... sales growth, INDIANAPOLIS, April 21 Eli ... financial results for the first quarter of,2008., ... and a pro forma,basis. Reported results were prepared ... include all sales and expenses recognized,by the company ...
... a researcher, please contact the Communications and External Relations staff ... information on ORNL and its research and development activities, please ... a general media-related question or comment, you can send it ... -- Protecting ports . . . , Knowing ...
... April 18 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today reported ... (NYSE: BSX ) has received approval ... coronary stent system in Canada.,BSC reported that ...
Cached Biology Technology:Lilly Reports Solid First-Quarter Results 2Lilly Reports Solid First-Quarter Results 3Lilly Reports Solid First-Quarter Results 4Lilly Reports Solid First-Quarter Results 5Lilly Reports Solid First-Quarter Results 6Lilly Reports Solid First-Quarter Results 7Lilly Reports Solid First-Quarter Results 8Lilly Reports Solid First-Quarter Results 9Lilly Reports Solid First-Quarter Results 10Lilly Reports Solid First-Quarter Results 11Lilly Reports Solid First-Quarter Results 12Lilly Reports Solid First-Quarter Results 13Lilly Reports Solid First-Quarter Results 14Lilly Reports Solid First-Quarter Results 15Lilly Reports Solid First-Quarter Results 16Lilly Reports Solid First-Quarter Results 17Story tips from the Department of Energy's Oak Ridge National Laboratory, March 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, March 2008 3Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 2Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 3Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 4
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... Administering stem cells derived from patients, own bone marrow either ... but does not improve heart function six months later, according ... Health (NIH). The results of the trial, called ... study, LateTIME, which found that such cells (called autologous stem ...
... factors responsible for symptoms such as headaches, gastro-intestinal disorders, ... unconsciousness and cardiac arrhythmia in severe cases. Histamine, one ... cause serious physical problems. Biogenic amines can be produced ... also ingested in larger quantities with food. They play ...
... developed a low-cost solution that could control the fungal disease ... tests are being carried out at Imperial College London,s Silwood ... The fungus Chalara fraxinea entered the country via ... led to the destruction of an estimated 100,000 diseased saplings ...
Cached Biology News:Bone marrow stem cells do not improve short-term recovery after heart attack 2Bone marrow stem cells do not improve short-term recovery after heart attack 3Development of measures to prevent wine indispositions 2Researchers test solution to fungal disease of ash trees 2Researchers test solution to fungal disease of ash trees 3
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... The GSTTag Monoclonal Antibody is a ... affinity to the 26 kDa glutathione-S-transferase ... This purified antibody is suitable for ... sequence expressed in E. coli , ...
... miRCURY Array LNA microarray slides for ... microarray slides incorporate Exiqons unique Locked Nucleic ... and excellent mismatch discrimination for short microRNA ... less than 1 g total RNA (no ...
... Although there have been many modifications to ... defined media, salt solutions still play an important ... to maintain the pH and osmotic balance in ... water and essential inorganic ions, is as valuable ...
Biology Products: